Rochester, NY - Researchers are calling for beta-blocker treatment for patients with intermittent claudication, arguing that it is "old school" to avoid them in this high-risk group [1]. The new study ...

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its ...

Although pentoxifylline and cilostazol may provide symptomatic relief, the management of IC must address the underlying problem of PVD. Resolution of risk factors, such as smoking, diabetes, ...

PAD patients with claudication undergoing peripheral vascular interventions (PVIs) in contemporary practice have a 4% risk of amputation within 4 years, with higher risk seen among those ...

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), ...

* Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo Source text for Eikon: Further company coverage: ...